Cargando…
Enhanced Therapeutic Efficacy of Combining Losartan and Chemo-Immunotherapy for Triple Negative Breast Cancer
Triple-negative breast cancer (TNBC) is a particularly aggressive subtype of breast cancer, which is relatively resistant to anti-programmed cell death-1 (α-PD1) therapy, characterized as non-immunogenic, dense stroma and accumulation of M2 tumor-associated macrophages (TAMs). Despite progress in st...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259940/ https://www.ncbi.nlm.nih.gov/pubmed/35812418 http://dx.doi.org/10.3389/fimmu.2022.938439 |
_version_ | 1784741900949913600 |
---|---|
author | Zhao, Qing He, Xuexin Qin, Xiyi Liu, Yu Jiang, Han Wang, Jing Wu, Shuang Zhou, Rui Yu, Congcong Liu, Suling Zhang, Hong Tian, Mei |
author_facet | Zhao, Qing He, Xuexin Qin, Xiyi Liu, Yu Jiang, Han Wang, Jing Wu, Shuang Zhou, Rui Yu, Congcong Liu, Suling Zhang, Hong Tian, Mei |
author_sort | Zhao, Qing |
collection | PubMed |
description | Triple-negative breast cancer (TNBC) is a particularly aggressive subtype of breast cancer, which is relatively resistant to anti-programmed cell death-1 (α-PD1) therapy, characterized as non-immunogenic, dense stroma and accumulation of M2 tumor-associated macrophages (TAMs). Despite progress in strategies to deplete extracellular matrix (ECM) and enhance tumor-cell immunogenicity, the combinatorial anti-cancer effects with α-PD1 need to be explored. Here, we applied doxorubicin hydrochloride liposome (Dox-L) as immunogenic cell death (ICD)-inducing nano-chemotherapy and used losartan as stroma-depleting agent to improve α-PD1 efficacy (Losartan + Dox-L + α-PD1). The results showed that losartan could cause ECM reduction, facilitating enhanced delivery of Dox-L and further dendritic cell (DC) maturation. Additionally, losartan could also alleviate hypoxia for TNBC, thus reprogramming pro-cancer M2 TAMs to anti-cancer M1 TAMs, successfully overcoming immune-suppressive microenvironment. These modifications led to a significant increase in T cells’ infiltration and augmented anti-tumor immunity as exemplified by the notable reduction in tumor size and lung metastases. In summary, our findings support that combined treatment of losartan with Dox-L normalizes immunological-cold microenvironment, improves immuno-stimulation and optimizes the efficacy of TNBC immunotherapy. A novel combinational strategy with FDA-approved compounds proposed by the study may potentially be useful in TNBC clinical treatment. |
format | Online Article Text |
id | pubmed-9259940 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92599402022-07-08 Enhanced Therapeutic Efficacy of Combining Losartan and Chemo-Immunotherapy for Triple Negative Breast Cancer Zhao, Qing He, Xuexin Qin, Xiyi Liu, Yu Jiang, Han Wang, Jing Wu, Shuang Zhou, Rui Yu, Congcong Liu, Suling Zhang, Hong Tian, Mei Front Immunol Immunology Triple-negative breast cancer (TNBC) is a particularly aggressive subtype of breast cancer, which is relatively resistant to anti-programmed cell death-1 (α-PD1) therapy, characterized as non-immunogenic, dense stroma and accumulation of M2 tumor-associated macrophages (TAMs). Despite progress in strategies to deplete extracellular matrix (ECM) and enhance tumor-cell immunogenicity, the combinatorial anti-cancer effects with α-PD1 need to be explored. Here, we applied doxorubicin hydrochloride liposome (Dox-L) as immunogenic cell death (ICD)-inducing nano-chemotherapy and used losartan as stroma-depleting agent to improve α-PD1 efficacy (Losartan + Dox-L + α-PD1). The results showed that losartan could cause ECM reduction, facilitating enhanced delivery of Dox-L and further dendritic cell (DC) maturation. Additionally, losartan could also alleviate hypoxia for TNBC, thus reprogramming pro-cancer M2 TAMs to anti-cancer M1 TAMs, successfully overcoming immune-suppressive microenvironment. These modifications led to a significant increase in T cells’ infiltration and augmented anti-tumor immunity as exemplified by the notable reduction in tumor size and lung metastases. In summary, our findings support that combined treatment of losartan with Dox-L normalizes immunological-cold microenvironment, improves immuno-stimulation and optimizes the efficacy of TNBC immunotherapy. A novel combinational strategy with FDA-approved compounds proposed by the study may potentially be useful in TNBC clinical treatment. Frontiers Media S.A. 2022-06-23 /pmc/articles/PMC9259940/ /pubmed/35812418 http://dx.doi.org/10.3389/fimmu.2022.938439 Text en Copyright © 2022 Zhao, He, Qin, Liu, Jiang, Wang, Wu, Zhou, Yu, Liu, Zhang and Tian https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Zhao, Qing He, Xuexin Qin, Xiyi Liu, Yu Jiang, Han Wang, Jing Wu, Shuang Zhou, Rui Yu, Congcong Liu, Suling Zhang, Hong Tian, Mei Enhanced Therapeutic Efficacy of Combining Losartan and Chemo-Immunotherapy for Triple Negative Breast Cancer |
title | Enhanced Therapeutic Efficacy of Combining Losartan and Chemo-Immunotherapy for Triple Negative Breast Cancer |
title_full | Enhanced Therapeutic Efficacy of Combining Losartan and Chemo-Immunotherapy for Triple Negative Breast Cancer |
title_fullStr | Enhanced Therapeutic Efficacy of Combining Losartan and Chemo-Immunotherapy for Triple Negative Breast Cancer |
title_full_unstemmed | Enhanced Therapeutic Efficacy of Combining Losartan and Chemo-Immunotherapy for Triple Negative Breast Cancer |
title_short | Enhanced Therapeutic Efficacy of Combining Losartan and Chemo-Immunotherapy for Triple Negative Breast Cancer |
title_sort | enhanced therapeutic efficacy of combining losartan and chemo-immunotherapy for triple negative breast cancer |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259940/ https://www.ncbi.nlm.nih.gov/pubmed/35812418 http://dx.doi.org/10.3389/fimmu.2022.938439 |
work_keys_str_mv | AT zhaoqing enhancedtherapeuticefficacyofcombininglosartanandchemoimmunotherapyfortriplenegativebreastcancer AT hexuexin enhancedtherapeuticefficacyofcombininglosartanandchemoimmunotherapyfortriplenegativebreastcancer AT qinxiyi enhancedtherapeuticefficacyofcombininglosartanandchemoimmunotherapyfortriplenegativebreastcancer AT liuyu enhancedtherapeuticefficacyofcombininglosartanandchemoimmunotherapyfortriplenegativebreastcancer AT jianghan enhancedtherapeuticefficacyofcombininglosartanandchemoimmunotherapyfortriplenegativebreastcancer AT wangjing enhancedtherapeuticefficacyofcombininglosartanandchemoimmunotherapyfortriplenegativebreastcancer AT wushuang enhancedtherapeuticefficacyofcombininglosartanandchemoimmunotherapyfortriplenegativebreastcancer AT zhourui enhancedtherapeuticefficacyofcombininglosartanandchemoimmunotherapyfortriplenegativebreastcancer AT yucongcong enhancedtherapeuticefficacyofcombininglosartanandchemoimmunotherapyfortriplenegativebreastcancer AT liusuling enhancedtherapeuticefficacyofcombininglosartanandchemoimmunotherapyfortriplenegativebreastcancer AT zhanghong enhancedtherapeuticefficacyofcombininglosartanandchemoimmunotherapyfortriplenegativebreastcancer AT tianmei enhancedtherapeuticefficacyofcombininglosartanandchemoimmunotherapyfortriplenegativebreastcancer |